Incyte Corporation
COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR
Last updated:
Abstract:
The present application provides combination therapies comprising a JAK inhibitor and a ROCK inhibitor, and methods of using the same to treat disorders such as graft versus host disease (GVHD), restrictive allograft syndrome (RAS), chronic lung allograft dysfunction (CLAD), and systemic sclerosis (scleroderma).
Status:
Application
Type:
Utility
Filling date:
10 Jan 2022
Issue date:
21 Jul 2022